Position in ABBV
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$44,400,366
-$5,568,797 QoQ
Shares Held
204,149
-6.7% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.24%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026AustralianSuper Pty Ltd holds $954,613,199 across 8 Drug Manufacturers - General names. ABBV ranks #7 (4.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
276,856 | $254,643,843 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
1,436,171 | $200,159,152 | |
| 3 | PFE |
Pfizer Inc
|
4,980,592 | $139,855,023 | |
| 4 | BMY |
Bristol Myers Squibb Co
|
2,125,356 | $128,902,841 | |
| 5 | BIIB |
Biogen Inc.
|
616,193 | $112,966,662 | |
| 6 | MRK |
Merck & Co., Inc.
|
575,397 | $69,214,505 | |
| 7 | ABBV |
AbbVie Inc.
This page
|
204,149 | $44,400,366 | |
| 8 | JNJ |
Johnson & Johnson
|
18,290 | $4,470,807 |
All Filings in ABBV
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $44,400,366 | 204,149 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $49,969,163 | 218,693 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $49,925,349 | 215,623 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $1,420,364 | 7,652 | Shares | Sole | 2025-08-01 | |
| 2025-03-31 | $1,599,475 | 7,634 | Shares | Sole | 2025-05-05 | |
| 2024-06-30 | $1,557,058 | 9,078 | Shares | Sole | 2024-07-26 | |
| 2024-03-31 | $1,524,359 | 8,371 | Shares | Sole | 2024-04-26 | |
| 2023-12-31 | $128,417,595 | 828,661 | Shares | Sole | 2024-01-16 | |
| 2023-09-30 | $1,402,654 | 9,410 | Shares | Sole | 2023-10-27 | |
| No filing history on record for this holder in this stock. | ||||||